Medications

Male birth control pill clears initial safety hurdle

YourChoice Therapeutics, working with Quotient Sciences and Incyte, reports that single oral doses of the investigational non‑hormonal male contraceptive YCT‑529 up to 180 mg produced no clinically relevant safety issues ...

Oncology & Cancer

Powering up T cells: A new path in cancer immunotherapy

Researchers have discovered a way to make the immune system's T cells significantly more effective at fighting cancer. By blocking a protein called Ant2, they were able to reprogram how these cells consume and generate energy—essentially ...

Inflammatory disorders

Intelligent wound dressing controls inflammation

Chronic wounds are a major medical challenge, burdening health care systems with billions of dollars in costs every year. Pioneer Fellow Börte Emiroglu is developing a new product: a selective, sponge-like hydrogel that ...

page 8 from 40